[96a5a0]: / output / allTrials / identified / NCT01433172_identified.json

Download this file

684 lines (684 with data), 30.1 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
{
"info": {
"nct_id": "NCT01433172",
"official_title": "A Randomized Phase I/II Trial Using a GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) Vaccine in Combination With CCL21 for Patients With Stage IV Adenocarcinoma of the Lung",
"inclusion_criteria": "* Histologically confirmed metastatic adenocarcinoma of the lung\n* Patients must have received and completed first line therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1\n* No external beam radiation therapy within 2 weeks of first vaccine administration\n* No stereotactic radiation therapy within 3 days of first vaccine\n* No targeted therapy within 2 weeks of first vaccine administration\n* No immunomodulatory therapy within 2 weeks of first vaccine administration\n* No chemotherapy within 4 weeks of first vaccine administration\n* During Screening period, no steroid therapy within 4 weeks of first vaccine administration\n* Patient's written informed consent\n* Adequate organ function (measured within a week of beginning treatment):\n\n * White blood count (WBC) > 3,000/mm³ and absolute neutrophil count (ANC) >/= 1500/mm³\n * Platelets > 100,000/mm³\n * Hematocrit > 25%\n * Bilirubin < 2.0 mg/dL\n * Creatinine < 2.0 mg/dL, or creatinine clearance > 60 mL/min\n* Patients will be tested for HLA-A0201 as determined by flow cytometry followed by molecular analysis of a peripheral blood specimen; however this result will not be an inclusion criterion.\n* Measurable metastatic tumor as defined by standard Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Lesions must be accurately measured in at least one dimension with the longest diameter ≥20 mm. With spiral computed tomography (CT) scan, lesion must be ≥10 mm in at least one dimension.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Symptomatic brain metastasis or Uncontrolled central nervous system (CNS) metastasis will not be permitted.\n* Any acute medical problems requiring active intervention\n* Current corticosteroid (other than replacement doses in patients who are hypo-adrenal) or other immunosuppressive therapy\n* Any other pre-existing immunodeficiency condition (including known human immunodeficiency virus [HIV] infection)\n* Any known pre-existing autoimmune disorder\n* History of a second malignancy within the previous 2 years (except non-melanoma skin cancer and cervical in-situ)\n* Patients who have had major surgery without full recovery or major surgery within three weeks of the start of vaccine treatment\n* Pregnant or lactating women: Patients in reproductive age must agree to use contraceptive methods for the duration of the study (*A pregnancy test will be obtained before treatment).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 2, 3, or 4\n* Patients with other significant diseases or disorders that, in the Investigator's opinion, would exclude them from the study.\n* Patients who at the discretion of the investigator are deemed to have rapidly progressive disease",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Histologically confirmed metastatic adenocarcinoma of the lung",
"criterions": [
{
"exact_snippets": "Histologically confirmed metastatic adenocarcinoma of the lung",
"criterion": "metastatic adenocarcinoma of the lung",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": "histologically confirmed"
}
]
}
]
},
{
"line": "* Patients must have received and completed first line therapy",
"criterions": [
{
"exact_snippets": "Patients must have received and completed first line therapy",
"criterion": "first line therapy",
"requirements": [
{
"requirement_type": "completion",
"expected_value": true
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"0",
"1"
]
}
]
}
]
},
{
"line": "* No external beam radiation therapy within 2 weeks of first vaccine administration",
"criterions": [
{
"exact_snippets": "No external beam radiation therapy within 2 weeks of first vaccine administration",
"criterion": "external beam radiation therapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* No stereotactic radiation therapy within 3 days of first vaccine",
"criterions": [
{
"exact_snippets": "No stereotactic radiation therapy within 3 days of first vaccine",
"criterion": "stereotactic radiation therapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "days"
}
}
]
}
]
},
{
"line": "* No targeted therapy within 2 weeks of first vaccine administration",
"criterions": [
{
"exact_snippets": "No targeted therapy within 2 weeks of first vaccine administration",
"criterion": "targeted therapy",
"requirements": [
{
"requirement_type": "time since last administration",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* No immunomodulatory therapy within 2 weeks of first vaccine administration",
"criterions": [
{
"exact_snippets": "No immunomodulatory therapy within 2 weeks of first vaccine administration",
"criterion": "immunomodulatory therapy",
"requirements": [
{
"requirement_type": "time since last administration",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* No chemotherapy within 4 weeks of first vaccine administration",
"criterions": [
{
"exact_snippets": "No chemotherapy within 4 weeks of first vaccine administration",
"criterion": "chemotherapy",
"requirements": [
{
"requirement_type": "time since last administration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* During Screening period, no steroid therapy within 4 weeks of first vaccine administration",
"criterions": [
{
"exact_snippets": "no steroid therapy within 4 weeks of first vaccine administration",
"criterion": "steroid therapy",
"requirements": [
{
"requirement_type": "time since last administration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Patient's written informed consent",
"criterions": [
{
"exact_snippets": "Patient's written informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Adequate organ function (measured within a week of beginning treatment):",
"criterions": [
{
"exact_snippets": "Adequate organ function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "measured within a week of beginning treatment",
"criterion": "measurement timing",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within a week of beginning treatment"
}
]
}
]
},
{
"line": "* White blood count (WBC) > 3,000/mm³ and absolute neutrophil count (ANC) >/= 1500/mm³",
"criterions": [
{
"exact_snippets": "White blood count (WBC) > 3,000/mm³",
"criterion": "white blood count (WBC)",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 3000,
"unit": "mm³"
}
}
]
},
{
"exact_snippets": "absolute neutrophil count (ANC) >/= 1500/mm³",
"criterion": "absolute neutrophil count (ANC)",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1500,
"unit": "mm³"
}
}
]
}
]
},
{
"line": "* Platelets > 100,000/mm³",
"criterions": [
{
"exact_snippets": "Platelets > 100,000/mm³",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">",
"value": 100000,
"unit": "mm³"
}
}
]
}
]
},
{
"line": "* Hematocrit > 25%",
"criterions": [
{
"exact_snippets": "Hematocrit > 25%",
"criterion": "hematocrit",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 25,
"unit": "%"
}
}
]
}
]
},
{
"line": "* Bilirubin < 2.0 mg/dL",
"criterions": [
{
"exact_snippets": "Bilirubin < 2.0 mg/dL",
"criterion": "bilirubin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 2.0,
"unit": "mg/dL"
}
}
]
}
]
},
{
"line": "* Creatinine < 2.0 mg/dL, or creatinine clearance > 60 mL/min",
"criterions": [
{
"exact_snippets": "Creatinine < 2.0 mg/dL",
"criterion": "creatinine level",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 2.0,
"unit": "mg/dL"
}
}
]
},
{
"exact_snippets": "creatinine clearance > 60 mL/min",
"criterion": "creatinine clearance",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 60,
"unit": "mL/min"
}
}
]
}
]
},
{
"line": "* Patients will be tested for HLA-A0201 as determined by flow cytometry followed by molecular analysis of a peripheral blood specimen; however this result will not be an inclusion criterion.",
"criterions": [
{
"exact_snippets": "HLA-A0201 as determined by flow cytometry followed by molecular analysis of a peripheral blood specimen",
"criterion": "HLA-A0201",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "tested"
}
]
}
]
},
{
"line": "* Measurable metastatic tumor as defined by standard Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Lesions must be accurately measured in at least one dimension with the longest diameter ≥20 mm. With spiral computed tomography (CT) scan, lesion must be ≥10 mm in at least one dimension.",
"criterions": [
{
"exact_snippets": "Measurable metastatic tumor",
"criterion": "metastatic tumor",
"requirements": [
{
"requirement_type": "measurability",
"expected_value": true
}
]
},
{
"exact_snippets": "Lesions must be accurately measured in at least one dimension with the longest diameter ≥20 mm",
"criterion": "lesion size",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 20,
"unit": "mm"
}
}
]
},
{
"exact_snippets": "With spiral computed tomography (CT) scan, lesion must be ≥10 mm in at least one dimension",
"criterion": "lesion size with CT scan",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 10,
"unit": "mm"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Symptomatic brain metastasis or Uncontrolled central nervous system (CNS) metastasis will not be permitted.",
"criterions": [
{
"exact_snippets": "Symptomatic brain metastasis",
"criterion": "brain metastasis",
"requirements": [
{
"requirement_type": "symptomatic",
"expected_value": false
}
]
},
{
"exact_snippets": "Uncontrolled central nervous system (CNS) metastasis",
"criterion": "central nervous system (CNS) metastasis",
"requirements": [
{
"requirement_type": "control",
"expected_value": "controlled"
}
]
}
]
},
{
"line": "* Any acute medical problems requiring active intervention",
"criterions": [
{
"exact_snippets": "acute medical problems requiring active intervention",
"criterion": "acute medical problems",
"requirements": [
{
"requirement_type": "intervention requirement",
"expected_value": true
}
]
}
]
},
{
"line": "* Current corticosteroid (other than replacement doses in patients who are hypo-adrenal) or other immunosuppressive therapy",
"criterions": [
{
"exact_snippets": "Current corticosteroid (other than replacement doses in patients who are hypo-adrenal)",
"criterion": "corticosteroid use",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "other immunosuppressive therapy",
"criterion": "immunosuppressive therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Any other pre-existing immunodeficiency condition (including known human immunodeficiency virus [HIV] infection)",
"criterions": [
{
"exact_snippets": "Any other pre-existing immunodeficiency condition",
"criterion": "pre-existing immunodeficiency condition",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "known human immunodeficiency virus [HIV] infection",
"criterion": "human immunodeficiency virus (HIV) infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Any known pre-existing autoimmune disorder",
"criterions": [
{
"exact_snippets": "Any known pre-existing autoimmune disorder",
"criterion": "autoimmune disorder",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* History of a second malignancy within the previous 2 years (except non-melanoma skin cancer and cervical in-situ)",
"criterions": [
{
"exact_snippets": "History of a second malignancy within the previous 2 years",
"criterion": "second malignancy",
"requirements": [
{
"requirement_type": "history",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "years"
}
}
]
},
{
"exact_snippets": "except non-melanoma skin cancer and cervical in-situ",
"criterion": "second malignancy exceptions",
"requirements": [
{
"requirement_type": "exceptions",
"expected_value": [
"non-melanoma skin cancer",
"cervical in-situ"
]
}
]
}
]
},
{
"line": "* Patients who have had major surgery without full recovery or major surgery within three weeks of the start of vaccine treatment",
"criterions": [
{
"exact_snippets": "Patients who have had major surgery without full recovery",
"criterion": "major surgery recovery",
"requirements": [
{
"requirement_type": "recovery status",
"expected_value": "not fully recovered"
}
]
},
{
"exact_snippets": "major surgery within three weeks of the start of vaccine treatment",
"criterion": "major surgery timing",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": "<",
"value": 3,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Pregnant or lactating women: Patients in reproductive age must agree to use contraceptive methods for the duration of the study (*A pregnancy test will be obtained before treatment).",
"criterions": [
{
"exact_snippets": "Pregnant or lactating women",
"criterion": "pregnancy or lactation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Patients in reproductive age must agree to use contraceptive methods",
"criterion": "use of contraceptive methods",
"requirements": [
{
"requirement_type": "agreement",
"expected_value": true
}
]
},
{
"exact_snippets": "A pregnancy test will be obtained before treatment",
"criterion": "pregnancy test",
"requirements": [
{
"requirement_type": "requirement",
"expected_value": "before treatment"
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 2, 3, or 4",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 2, 3, or 4",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"2",
"3",
"4"
]
}
]
}
]
},
{
"line": "* Patients with other significant diseases or disorders that, in the Investigator's opinion, would exclude them from the study.",
"criterions": [
{
"exact_snippets": "other significant diseases or disorders",
"criterion": "significant diseases or disorders",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients who at the discretion of the investigator are deemed to have rapidly progressive disease",
"criterions": [
{
"exact_snippets": "rapidly progressive disease",
"criterion": "disease progression",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "rapidly progressive"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}